Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.
Helio P GuimarãesRenato D LopesPedro G M de Barros E SilvaIdelzuita L LiporaceRoney O SampaioFlávio TarasoutchiConrado R Hoffmann-FilhoRodrigo de Lemos S PatriotaTiago L L LeiriaDiana LampreaDalton B PrecomaFernando A AtikFabio S SilveiraFabio R FariasDiogo O BarretoAdail P AlmeidaAlexandre C ZilliJoão D de Souza NetoMargaret A CavalcanteFernando A M S FigueiraFlávia C S KojimaLucas DamianiRenato H N SantosNanci ValeisViviane B CamposJose F K SaraivaFrancisco H FonsecaIbraim M PintoCarlos C MagalhãesJoao F M FerreiraJohn H AlexanderRicardo PavanelloAlexandre B CavalcantiOtavio Berwangernull nullPublished in: The New England journal of medicine (2020)
In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. (Funded by PROADI-SUS and Bayer; RIVER ClinicalTrials.gov number, NCT02303795.).